Evogene : Biomica’s presentation at 5th Microbiome Movement Drug Development Europe Conference 2021

BIOMICA

Microbiome-Empowered Therapeutics

Microbiome Movement Drug Development Summit EU January 2021

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries, including Biomica Ltd. ("Biomica") (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward- looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Biomica claims the protection of the safe harbor for forward-looking statements contained in the PSLRA and other securities laws.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Biomica and Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Biomica's and Evogene's control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information it files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Biomica and Evogene disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

2

Founded Israel, 2017

Subsidiary of Evogene Ltd.

(NASDAQ, TASE: EVGN)

A pioneer in the field of applied computational predictive biology

Holds Approx. 90%

HIGHLIGHTS

Mission

Developing innovative microbiome-based therapeutics

Emerging biopharmaceutical company

Focus

Treatment of immune-mediated and infectious diseases:

• Immuno-Oncology
• Gastrointestinal (GI) related disorders
• Antimicrobial resistance (AMR)

Pipeline

Enabled by a unique computational predictive biology platform (combining 'Big-Data' & Artificial Intelligence technologies)

3

Trillions of microbes living in & on our bodies, acting as a "Other Genome"

For every human gene there are 100 microbial genes

The Microbiome and its Functions

The human gastrointestinal tract

comprises approximately 1014

microbes and amounts to a biomass

of approximately 2kg!

Microbes play a critical		Clinical evidence is		Solving dysbiosis, a state
role in food digestion,		accumulating for		of microbial imbalance
protection from		microbiome's role in a		in the body, is at the
diseases and		wide array of illnesses		core of new therapeutic
production of nutrients				approaches